$XTALPI(02228.HK) Recently, during a leadership visit, the drug shown in the pictures was a treatment for diffuse gastric cancer developed in collaboration with Xige Biotech, the same drug that was nominated for a major award last year. Currently in Phase II clinical trials in the U.S., progress is smooth, and it has also shown promising results in treating abdominal ascites. Given that diffuse gastric cancer is a rare disease in the U.S., Phase III clinical trials might be waived. This means the drug could potentially be approved for the U.S. market in the near future, with accelerated introduction to the domestic market also possible. This should be good news.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
